Receptor, Fibroblast Growth Factor, Type 3 - Genetics
Research News and Information

Monday, November 23, 2009

Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development.

30 Oct 2009 Bladder cancer develops through different pathways, provisionally entitled "papillary" and "invasive." Carcinoma in situ (CIS) is thought to be the precursor of invasive bladder cancer. However, little is known about chromosomal alterations of these ... Read more...

No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.

30 Oct 2009 Mutations in the fibroblast growth factor receptor 3 (FGFR3) gene causing constitutive oncogenic protein activation have been shown to be frequent in papillary noninvasive bladder tumours and are associated with a low risk of progression and a ... Read more...

Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.

10 Aug 2009 FGF19 is a hormone that regulates bile acid and glucose homeostasis. Progress has been made in identifying cofactors for receptor activation. However, several functions of FGF19 have not yet been fully defined, including the actions of FGF19 on ... Read more...

Latest indexed articles for 'Receptor, Fibroblast Growth Factor, Type 3 - Genetics'

These are the very latest articles for this heading:

• FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma. 30 Oct 2009
• Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. 30 Oct 2009
• No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. 30 Oct 2009
• Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. 10 Aug 2009
• Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. 30 Jul 2009
• Plasma cell myeloma. 30 Jul 2009
• Acanthosis nigricans and insulin sensitivity in patients with achondroplasia and hypochodroplasia due to FGFR3 mutations. 19 Jul 2009
• FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14). 4 Jul 2009
• The absence of BRAF, FGFR3, and PIK3CA mutations differentiates lentigo simplex from melanocytic nevus and solar lentigo. 16 Jun 2009
• Significant phenotypic variability of Muenke syndrome in identical twins. 30 May 2009
• Thanatophoric dysplasia caused by double missense FGFR3 mutations. 30 May 2009
• Stiff skin syndrome: evidence for an inflammation-independent fibrosis? 23 May 2009
• Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. 17 May 2009
• A young patient with polyarthralgia and hearing loss: a case report of Muenke syndrome. 14 May 2009
• Methylation status of CpG islands in the promoter regions of signature genes during chondrogenesis of human synovium-derived mesenchymal stem cells. 29 Apr 2009
• The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. 29 Apr 2009
• Fibroblast growth factor receptor-3 regulates Paneth cell lineage allocation and accrual of epithelial stem cells during murine intestinal development. 28 Apr 2009
• Remodeling of chromatin structure within the promoter is important for bmp-2-induced fgfr3 expression. 26 Apr 2009
• The G1138A mutation rate in the fibroblast growth factor receptor 3 (FGFR3) gene is increased in cells carrying the t (4; 14) translocation. 20 Apr 2009
• FGFR3 mutations in prostate cancer: association with low-grade tumors. 15 Apr 2009

See a longer list of these articles.

Technical information about 'Receptor, Fibroblast Growth Factor, Type 3'

Definition: A fibroblast growth factor receptor that regulates CHONDROCYTE growth and CELL DIFFERENTIATION. Mutations in the gene for fibroblast growth factor receptor 3 have been associated with ACHONDROPLASIA; THANATOPHORIC DYSPLASIA and NEOPLASTIC CELL TRANSFORMATION.

Registry Number: EC 2.7.1.112

Descriptor UI: D051498

Alternative terms: Receptor, Fibroblast Growth Factor, Type 3; Fibroblast Growth Factor Receptors 3; Fibroblast Growth Factor Receptor 3; FGFR3 Protein; Receptor 3, Fibroblast Growth Factor;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D08.811.913.696.620.682.725.400.179; D12.776.543.750.060.442; D12.776.543.750.750.400.370.875; D12.776.624.664.700.792;

History Note: 2006(1992)